StockData
Achieve Life Sciences, Inc. logo

Achieve Life Sciences, Inc. (ACHV) stock

ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as QUIT
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$6.61+0.23 (+3.53%)

Close on Oct 19, 2026Market cap $679.67MP/E –Yield –

Achieve Life Sciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Achieve Life Sciences's free cash flow for the twelve months ending Dec 31, 2023 was -$24.50M. For fiscal 2025 it was -$49.47M. The highest annual figure on record is $34.86M in fiscal 2009.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$49.47M–
FY2023Dec 31, 2023-$24.50M–
FY2020Dec 31, 2020-$13.49M–
FY2019Dec 31, 2019-$15.27M–
FY2018Dec 31, 2018-$10.67M–
FY2016Dec 31, 2016-$248.00K–
FY2015Dec 31, 2015-$721.00K–
FY2014Dec 31, 2014-$17.39M–
FY2013Dec 31, 2013-$36.18M–
FY2012Dec 31, 2012-$43.78M–
FY2011Dec 31, 2011-$20.34M–
FY2010Dec 31, 2010-$26.91M-177.2%
FY2009Dec 31, 2009$34.86M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$4.37M–
Q4 FY2020Dec 31, 2020-$2.48M–
Q3 FY2020Sep 30, 2020-$4.34M–
Q2 FY2020Jun 30, 2020-$2.21M–
Q1 FY2020Mar 31, 2020-$4.46M–
Q4 FY2019Dec 31, 2019-$3.42M–
Q3 FY2019Sep 30, 2019-$3.07M–
Q2 FY2019Jun 30, 2019-$3.84M–
Q1 FY2019Mar 31, 2019-$4.94M–
Q4 FY2018Dec 31, 2018-$3.55M–
Q3 FY2018Sep 30, 2018-$2.98M-119.5%
Q2 FY2017Jun 30, 2017-$18.00K–
Q1 FY2017Mar 31, 2017-$12.00K–
Q4 FY2016Dec 31, 2016-$69.00K–
Q3 FY2016Sep 30, 2016$15.30M–

More Achieve Life Sciences figures

See a number that looks wrong?